Unjha Formul.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE576D01015
NSEID:
BSEID: 531762

INR

23.62

-1.57 (-6.23%)

BSENSE

Dec 05

BSE+NSE Vol: 16

{
  "main_header": {
    "sid": 782664,
    "name": "Unjha Formul.",
    "stock_name": "Unjha Formul.",
    "full_name": "Unjha Formulations Ltd",
    "name_url": "stocks-analysis/unjha-formul",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "23.62",
    "chg": -1.57,
    "chgp": "-6.23%",
    "dir": -1,
    "prev_price": "25.19",
    "mcapval": "11.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531762,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE576D01015",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "16 ",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/unjha-formul-782664-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Unjha Formulations Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/unjha-formulations-downgraded-to-sell-amid-mixed-financial-and-technical-signals-3740563",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/UnjhaFormulatio_mojoScore_3740563.png",
        "date": "2025-12-02 08:19:35",
        "description": "Unjha Formulations, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in market assessment driven by a combination of technical trends, valuation metrics, financial performance, and broader market returns. This article analyses the key factors influencing the recent revision in the company’s evaluation, providing investors with a comprehensive understanding of the current landscape."
      },
      {
        "title": "How has been the historical performance of Unjha Formul.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-unjha-formul-3739206",
        "imagepath": "",
        "date": "2025-12-01 23:06:41",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Operating Performance Trends</strong></p>\n<p>Over the past seven years, Unjha Formul.'s net sales have demonstrated notable volatility. The company recorded a peak in total operating income in the fiscal year ending March 2024, followed by a decline in the subsequent year. Earlier years showed moderate growth from fiscal 2019 to 2021, with sales rising from just over ₹11 crores to nearly ₹10 crores, before surging to above ₹18 crores in 2024. However, the latest fiscal year saw a contraction to under ₹14 crores, indicating challenges in sustaining top-line momentum.</p>\n<p>Raw material costs have consistently represented the largest expenditure, closely tracking revenue fluctuations. These costs peaked alongside sales in 2024 but decreased in line with the revenue dip in 2025. Em..."
      },
      {
        "title": "Why is Unjha Formul. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-unjha-formul-fallingrising-3716043",
        "imagepath": "",
        "date": "2025-11-19 22:09:44",
        "description": "As of 19-Nov, Unjha Formulations Ltd is currently priced at 26.40, reflecting an increase of 0.7, or 2.72%. The stock has shown strong performance in the short term, with a 1-week return of 6.02% and a 1-month return of 9.91%, both significantly outperforming the Sensex, which returned 0.85% and 1.47% respectively. Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend. However, there has been a notable decline in investor participation, with delivery volume dropping by 83.62% compared to the 5-day average, which could raise concerns about the sustainability of the recent price increase. There are no specific positive or negative factors available to further explain the stock's recent movement.\n\nBroader Market Context: In the context of the broader market, Unjha Formulations Ltd's recent short-term performance stands out, particu..."
      },
      {
        "title": "Why is Unjha Formul. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-unjha-formul-fallingrising-3698550",
        "imagepath": "",
        "date": "2025-11-13 22:02:09",
        "description": "As of 13-Nov, Unjha Formulations Ltd is experiencing a price increase, with its current price at Rs 26.99, reflecting a rise of Rs 2.09 or 8.39%. The stock opened with a gain of 2.29% today and reached an intraday high of Rs 27.5, marking a 10.44% increase. Additionally, Unjha Formulations has outperformed its sector by 8.18%. Over the past week, the stock has shown a significant return of +17.40%, while its performance over the last month is +10.98%. However, there has been a decline in investor participation, with delivery volume dropping by 17.42% compared to the 5-day average, which may indicate a potential concern for sustained momentum.\n\nBroader Market Context: In comparison to the benchmark Sensex, which has increased by 1.40% over the past week and 2.61% over the past month, Unjha Formulations has significantly outperformed in the short term. Despite a year-to-date decline of 11.19% against the Sens..."
      },
      {
        "title": "Unjha Formulations Reports Strong Financial Performance Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/unjha-formulations-financial-trend-improves-from-negative-to-positive-amid-strong-performance-metrics-3697424",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/UnjhaFormulatio_fintrenddot_3697424.png",
        "date": "2025-11-13 11:03:26",
        "description": "Unjha Formulations has reported strong financial performance for the quarter ending September 2025, achieving record figures in key metrics such as PBDIT, PBT, and PAT. The company's stock has shown volatility, with notable fluctuations in price, while long-term returns have significantly outperformed the Sensex."
      },
      {
        "title": "Unjha Formulations Q2 FY26: Micro-Cap Pharma Posts Highest Quarterly Profit Despite Valuation Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/unjha-formulations-q2-fy26-micro-cap-pharma-posts-highest-quarterly-profit-despite-valuation-concerns-3698424",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/UnjhaFormulatio_quaterlyResult_3698424.png",
        "date": "2025-11-13 09:35:42",
        "description": "Unjha Formulations Ltd., a Gujarat-based micro-cap pharmaceutical company specialising in Isabgol (Psyllium) formulations, reported its highest-ever quarterly net profit of ₹0.82 crores in Q2 FY26, marking a substantial turnaround from previous quarters. The company's net profit surged 110.26% quarter-on-quarter (QoQ) and reversed from a loss of ₹0.11 crores in Q2 FY25, representing a year-on-year (YoY) swing into profitability. However, despite these improved operational metrics, the stock trades at a \"Very Expensive\" valuation with a market capitalisation of just ₹11.00 crores, raising questions about sustainability and investor expectations."
      },
      {
        "title": "Is Unjha Formul. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-unjha-formul-overvalued-or-undervalued-3696161",
        "imagepath": "",
        "date": "2025-11-13 08:11:54",
        "description": "As of 12 November 2025, the valuation grade for Unjha Formul. has moved from very expensive to very attractive, indicating a significant shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 11.08, an EV to EBIT of 10.66, and an impressive ROE of 32.48%. \n\nIn comparison to its peers, Unjha Formul. stands out with a PEG ratio of 0.40, while Sun Pharma. Inds. has a PE of 35.94 and Divi's Lab. shows a staggering PE of 69.64, both categorized as expensive. The attractive valuation of Unjha Formul. is further supported by its strong performance metrics, particularly its ROCE of 16.80%. Despite recent underperformance in the YTD return compared to the Sensex, the long-term performance over 3 years and 5 years shows a remarkable return of 149.21% and 250.28%, respectively, reinforcing the attractiveness of its current valuation...."
      },
      {
        "title": "How has been the historical performance of Unjha Formul.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-unjha-formul-3695173",
        "imagepath": "",
        "date": "2025-11-13 00:10:13",
        "description": "Answer:\nThe historical performance of Unjha Formul shows fluctuations in net sales and profitability over the years, with net sales reaching 13.86 Cr in Mar'25, down from 18.50 Cr in Mar'24, but up from 13.15 Cr in Mar'23. The total operating income followed a similar trend, peaking at 18.50 Cr in Mar'24 before declining to 13.86 Cr in Mar'25. The company’s operating profit (PBDIT) was 0.62 Cr in Mar'25, slightly up from 0.59 Cr in Mar'24, indicating a stable operating profit margin of 3.68% in Mar'25 compared to 3.14% in the previous year. Profit before tax also increased to 0.52 Cr in Mar'25 from 0.45 Cr in Mar'24, while profit after tax rose to 0.41 Cr in Mar'25, up from 0.28 Cr in Mar'24. The earnings per share (EPS) improved to 0.92 in Mar'25 from 0.62 in Mar'24, reflecting a positive trend in profitability.\n\nBreakdown:\nUnjha Formul's financial performance over the years indicates a volatile yet improv..."
      },
      {
        "title": "How has been the historical performance of Unjha Formul.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-unjha-formul-3693759",
        "imagepath": "",
        "date": "2025-11-12 23:12:50",
        "description": "Answer:\nThe historical performance of Unjha Formul shows a fluctuating trend in net sales and profitability over the years, with a notable decline in recent periods.\n\nBreakdown:\nUnjha Formul's net sales peaked at 18.50 Cr in March 2024 but fell to 13.86 Cr in March 2025, reflecting a downward trend. The total operating income followed a similar pattern, decreasing from 18.50 Cr in March 2024 to 13.86 Cr in March 2025. Raw material costs also decreased from 15.55 Cr in March 2024 to 11.32 Cr in March 2025, while total expenditure, excluding depreciation, dropped from 17.92 Cr to 13.35 Cr in the same period. Operating profit (PBDIT) showed a slight increase from 0.58 Cr in March 2024 to 0.62 Cr in March 2025, indicating improved operational efficiency despite lower sales. Profit before tax rose from 0.45 Cr to 0.52 Cr, and profit after tax increased from 0.28 Cr to 0.41 Cr, resulting in an earnings per share ..."
      }
    ],
    "total": 126,
    "sid": "782664",
    "stock_news_url": "https://www.marketsmojo.com/news/unjha-formulations-782664"
  },
  "announcements": [
    {
      "caption": "Publish Un-Audited Financial Results For The Quarter & Half Year Ended As On 30/09/2025",
      "datetime": "12-Nov-2025",
      "details": "Regulation 33(3) of SEBI (LODR)Act 2015",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for : Approval Of Un-Audited Financial Results Of The Company For Quarter Ended And Half Year Ended On 30Th September2025 And Out Come Of Board Meeting Held On 10Th November 2025",
      "datetime": "10-Nov-2025",
      "details": "REGULATION 33 OF SEBI LODR 2015.",
      "source": "BSE"
    },
    {
      "caption": "Approval Of Un-Audited Financial Results Of The Company For Quarter Ended And Half Year Ended On 30Th September2025 And Out Come Of Board Meeting Held On 10Th November 2025",
      "datetime": "10-Nov-2025",
      "details": "Regulation 33 of SEBI LODR 2015",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Unjha Formulations Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals

2025-12-02 08:19:35

Unjha Formulations, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in market assessment driven by a combination of technical trends, valuation metrics, financial performance, and broader market returns. This article analyses the key factors influencing the recent revision in the company’s evaluation, providing investors with a comprehensive understanding of the current landscape.

How has been the historical performance of Unjha Formul.?

2025-12-01 23:06:41

Revenue and Operating Performance Trends

Over the past seven years, Unjha Formul.'s net sales have demonstrated notable volatility. The company recorded a peak in total operating income in the fiscal year ending March 2024, followed by a decline in the subsequent year. Earlier years showed moderate growth from fiscal 2019 to 2021, with sales rising from just over ₹11 crores to nearly ₹10 crores, before surging to above ₹18 crores in 2024. However, the latest fiscal year saw a contraction to under ₹14 crores, indicating challenges in sustaining top-line momentum.

Raw material costs have consistently represented the largest expenditure, closely tracking revenue fluctuations. These costs peaked alongside sales in 2024 but decreased in line with the revenue dip in 2025. Em...

Why is Unjha Formul. falling/rising?

2025-11-19 22:09:44

As of 19-Nov, Unjha Formulations Ltd is currently priced at 26.40, reflecting an increase of 0.7, or 2.72%. The stock has shown strong performance in the short term, with a 1-week return of 6.02% and a 1-month return of 9.91%, both significantly outperforming the Sensex, which returned 0.85% and 1.47% respectively. Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend. However, there has been a notable decline in investor participation, with delivery volume dropping by 83.62% compared to the 5-day average, which could raise concerns about the sustainability of the recent price increase. There are no specific positive or negative factors available to further explain the stock's recent movement. Broader Market Context: In the context of the broader market, Unjha Formulations Ltd's recent short-term performance stands out, particu...

Why is Unjha Formul. falling/rising?

2025-11-13 22:02:09

As of 13-Nov, Unjha Formulations Ltd is experiencing a price increase, with its current price at Rs 26.99, reflecting a rise of Rs 2.09 or 8.39%. The stock opened with a gain of 2.29% today and reached an intraday high of Rs 27.5, marking a 10.44% increase. Additionally, Unjha Formulations has outperformed its sector by 8.18%. Over the past week, the stock has shown a significant return of +17.40%, while its performance over the last month is +10.98%. However, there has been a decline in investor participation, with delivery volume dropping by 17.42% compared to the 5-day average, which may indicate a potential concern for sustained momentum. Broader Market Context: In comparison to the benchmark Sensex, which has increased by 1.40% over the past week and 2.61% over the past month, Unjha Formulations has significantly outperformed in the short term. Despite a year-to-date decline of 11.19% against the Sens...

Unjha Formulations Reports Strong Financial Performance Amid Market Volatility

2025-11-13 11:03:26

Unjha Formulations has reported strong financial performance for the quarter ending September 2025, achieving record figures in key metrics such as PBDIT, PBT, and PAT. The company's stock has shown volatility, with notable fluctuations in price, while long-term returns have significantly outperformed the Sensex.

Unjha Formulations Q2 FY26: Micro-Cap Pharma Posts Highest Quarterly Profit Despite Valuation Concerns

2025-11-13 09:35:42

Unjha Formulations Ltd., a Gujarat-based micro-cap pharmaceutical company specialising in Isabgol (Psyllium) formulations, reported its highest-ever quarterly net profit of ₹0.82 crores in Q2 FY26, marking a substantial turnaround from previous quarters. The company's net profit surged 110.26% quarter-on-quarter (QoQ) and reversed from a loss of ₹0.11 crores in Q2 FY25, representing a year-on-year (YoY) swing into profitability. However, despite these improved operational metrics, the stock trades at a "Very Expensive" valuation with a market capitalisation of just ₹11.00 crores, raising questions about sustainability and investor expectations.

Is Unjha Formul. overvalued or undervalued?

2025-11-13 08:11:54

As of 12 November 2025, the valuation grade for Unjha Formul. has moved from very expensive to very attractive, indicating a significant shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 11.08, an EV to EBIT of 10.66, and an impressive ROE of 32.48%. In comparison to its peers, Unjha Formul. stands out with a PEG ratio of 0.40, while Sun Pharma. Inds. has a PE of 35.94 and Divi's Lab. shows a staggering PE of 69.64, both categorized as expensive. The attractive valuation of Unjha Formul. is further supported by its strong performance metrics, particularly its ROCE of 16.80%. Despite recent underperformance in the YTD return compared to the Sensex, the long-term performance over 3 years and 5 years shows a remarkable return of 149.21% and 250.28%, respectively, reinforcing the attractiveness of its current valuation....

How has been the historical performance of Unjha Formul.?

2025-11-13 00:10:13

Answer: The historical performance of Unjha Formul shows fluctuations in net sales and profitability over the years, with net sales reaching 13.86 Cr in Mar'25, down from 18.50 Cr in Mar'24, but up from 13.15 Cr in Mar'23. The total operating income followed a similar trend, peaking at 18.50 Cr in Mar'24 before declining to 13.86 Cr in Mar'25. The company’s operating profit (PBDIT) was 0.62 Cr in Mar'25, slightly up from 0.59 Cr in Mar'24, indicating a stable operating profit margin of 3.68% in Mar'25 compared to 3.14% in the previous year. Profit before tax also increased to 0.52 Cr in Mar'25 from 0.45 Cr in Mar'24, while profit after tax rose to 0.41 Cr in Mar'25, up from 0.28 Cr in Mar'24. The earnings per share (EPS) improved to 0.92 in Mar'25 from 0.62 in Mar'24, reflecting a positive trend in profitability. Breakdown: Unjha Formul's financial performance over the years indicates a volatile yet improv...

How has been the historical performance of Unjha Formul.?

2025-11-12 23:12:50

Answer: The historical performance of Unjha Formul shows a fluctuating trend in net sales and profitability over the years, with a notable decline in recent periods. Breakdown: Unjha Formul's net sales peaked at 18.50 Cr in March 2024 but fell to 13.86 Cr in March 2025, reflecting a downward trend. The total operating income followed a similar pattern, decreasing from 18.50 Cr in March 2024 to 13.86 Cr in March 2025. Raw material costs also decreased from 15.55 Cr in March 2024 to 11.32 Cr in March 2025, while total expenditure, excluding depreciation, dropped from 17.92 Cr to 13.35 Cr in the same period. Operating profit (PBDIT) showed a slight increase from 0.58 Cr in March 2024 to 0.62 Cr in March 2025, indicating improved operational efficiency despite lower sales. Profit before tax rose from 0.45 Cr to 0.52 Cr, and profit after tax increased from 0.28 Cr to 0.41 Cr, resulting in an earnings per share ...

View All News